OptimizeRx director Spangler sells $194k in shares

Published 11/09/2025, 19:00
OptimizeRx director Spangler sells $194k in shares

Director Patrick D. Spangler of OptimizeRx Corp (NASDAQ:OPRX) sold 11,120 shares of common stock on August 28, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at prices ranging from $17.47 to $18.43, for a total value of $194,488. The transaction comes as OptimizeRx shares trade near their 52-week high of $19.25, having delivered an impressive 324% return over the past six months. According to InvestingPro analysis, the company maintains a GREAT financial health score, with analysts setting price targets ranging from $11 to $27.

Following the transaction, Spangler directly owns 44,215 shares of OptimizeRx Corp. Want deeper insights into insider transactions and comprehensive analysis? InvestingPro offers exclusive access to detailed insider trading patterns and 13 additional key insights about OPRX’s valuation and growth prospects.

In other recent news, OptimizeRx Corp. reported impressive second-quarter financial results, with revenue reaching $29.2 million, marking a 55% increase from the previous year. This figure significantly surpassed analyst estimates, including JMP Securities’ projection of $22.2 million and the consensus expectation of $22.3 million. The company’s earnings per share (EPS) also surprised analysts, coming in at $0.24 compared to the forecasted $0.02, a remarkable 1100% increase. Following these strong earnings, JMP Securities raised its price target for OptimizeRx from $14 to $20, maintaining a Market Outperform rating. Additionally, OptimizeRx has announced a series of leadership changes as part of its "Rule of 40" strategy to drive growth and profitability over the next few years. Ed Stelmakh has been appointed as Chief Financial & Strategic Officer, expanding his role to include broader corporate strategy alongside financial leadership. These developments reflect the company’s ongoing efforts to strengthen its market position and enhance shareholder value.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.